BMS gets EC approval for Opdivo combination to treat gastrointestinal cancers
The EC approval was based on results from the Phase 3 CheckMate-649 trial, which showed positive outcomes for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Oct 21
The EC approval was based on results from the Phase 3 CheckMate-649 trial, which showed positive outcomes for…
22 Oct 21
The agreement extends Novartis’ earlier supply agreement for the fill and finish of more than 50 million doses…
21 Oct 21
The US FDA has also authorised the use of heterologous booster dose of Covid-19 vaccines, in addition to…
20 Oct 21
The difference between potassium chloride and its healthier alternative, potassium salt, is increasingly important in a world of…
20 Oct 21
Zuranolone is an oral, once-daily, two-week therapy intended to treat major depressive disorder (MDD) and postpartum depression (PPD)
20 Oct 21
Lenalidomide is a generic version of Celgene’s Revlimid, intended to treat multiple myeloma (MM), myelodysplastic syndromes (MDS), and…
19 Oct 21
Biktarvy is a once-daily dosing complete HIV-1 treatment comprising three medicines, with a limited drug interaction potential and…
19 Oct 21
The regulatory submission is based on data from the Phase 2/3 study of the Comirnaty 10μg dose in…
18 Oct 21
The FDA approval is based on the Phase 3 IMpower010 study, which showed that adjuvant Tecentriq improved disease-free…
18 Oct 21
The recommendation is based on results from two clinical trials, including the Phase 3 ENSEMBLE 2 study, and…